Oxford Pharmascience completes next step in Safestat programme

Oxford Pharmascience, a speciality pharmaceutical company, has successfully completed the formulation development for its Safestat drugs, Atorvastatin and Simvastatin.

Oxford Pharmascience, a speciality pharmaceutical company, has successfully completed the formulation development for its Safestat drugs, Atorvastatin and Simvastatin.

The developments continue the company's Safestat programme, which aims to re-formulate the widely used molecules of atorvastatin and simvastatin into doses up to four times lower than the original dose, but with the same lipid-lowering properties as the original higher dose.

Marcelo Bravo, Chief Technology Officer of Oxford Pharmascience said: "Completion of formulation development is a first important milestone in the Safestat programme and we are now ready to proceed to manufacture of GMP products for use in proof of concept clinical trials during 2013."

The company said it has now developed and optimised formulations of both atorvastatin and simvastatin and proven in-vitro release under simulated human conditions.

The share price rose 29.91% to 3.48p by 14:10.

NR

Recommended

Share tips of the week – 24 September
Share tips

Share tips of the week – 24 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
24 Sep 2021
Three strong Asian stocks trading at bargain prices
Share tips

Three strong Asian stocks trading at bargain prices

Professional investor Nitin Bajaj of the Fidelity Asian Values investment trust picks three stocks that dominate their industries, earn good returns o…
20 Sep 2021
Why it pays to face up to your investment mistakes
Investment strategy

Why it pays to face up to your investment mistakes

Buying stocks can be a complicated business. But selling stocks can be tricky, too – even if you sell for the right reasons. Max King explains how to …
17 Sep 2021
Share tips of the week – 17 September
Share tips

Share tips of the week – 17 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
17 Sep 2021

Most Popular

A nightmare 1970s scenario for investors is edging closer
Investment strategy

A nightmare 1970s scenario for investors is edging closer

Inflation need not be a worry unless it is driven by labour market shortages. Unfortunately, writes macroeconomist Philip Pilkington, that’s exactly w…
17 Sep 2021
Two shipping funds to buy for steady income
Investment trusts

Two shipping funds to buy for steady income

Returns from owning ships are volatile, but these two investment trusts are trying to make the sector less risky.
7 Sep 2021
Should investors be worried about stagflation?
US Economy

Should investors be worried about stagflation?

The latest US employment data has raised the ugly spectre of “stagflation” – weak growth and high inflation. John Stepek looks at what’s going on and …
6 Sep 2021